$FOLD, Amicus Therapeutics, Inc. (FOLD) Updat
Post# of 23076
Posted On: 08/23/2016 8:09:45 AM
$FOLD,
Amicus Therapeutics, Inc. (FOLD) Updated Price Targets
By Warren Smith / in US Broker Ratings / on Tuesday, 23 Aug 2016 07:03 AM / 0 Comments
Recently analysts working for numerous investment brokerages have updated their research report ratings and price targets on shares of Amicus Therapeutics, Inc. (FOLD).
Recent broker ratings and price targets:
06/14/2016 – Amicus Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 19 price target on the stock.
05/18/2016 – Bank of America Merrill Lynch began new coverage on Amicus Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 10 price target on the stock.
04/13/2016 – Robert W. Baird began new coverage on Amicus Therapeutics, Inc. giving the company a “neutral” rating. They now have a USD 9 price target on the stock.
04/12/2016 – Amicus Therapeutics, Inc. had its “buy” rating reiterated by analysts at Chardan Capital. They now have a USD 15 price target on the stock.
03/30/2016 – Amicus Therapeutics, Inc. had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 10 price target on the stock.
03/08/2016 – Amicus Therapeutics, Inc. was upgraded to “buy” by analysts at Janney Montgomery Scott.
10/05/2015 – Amicus Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 13 price target on the stock.
09/08/2015 – Amicus Therapeutics, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 28 price target on the stock.
06/16/2015 – Amicus Therapeutics, Inc. had its “buy” rating reiterated by analysts at B. Riley. They now have a USD 17.5 price target on the stock.
05/08/2015 – Amicus Therapeutics, Inc. was downgraded to “sell” by analysts at Zacks.
Amicus Therapeutics, Inc. has a 50 day moving average of 6.43 and a 200 day moving average of 6.86. The stock’s market capitalization is 1.02B, it has a 52-week low of 4.98 and a 52-week high of 18.40.
The share price of the company (FOLD) was up +2.56%, with a high of 7.20 during the day and the volume of Amicus Therapeutics, Inc. shares traded was 1317417.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.
Amicus Therapeutics, Inc. (FOLD) Updated Price Targets
By Warren Smith / in US Broker Ratings / on Tuesday, 23 Aug 2016 07:03 AM / 0 Comments
Recently analysts working for numerous investment brokerages have updated their research report ratings and price targets on shares of Amicus Therapeutics, Inc. (FOLD).
Recent broker ratings and price targets:
06/14/2016 – Amicus Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 19 price target on the stock.
05/18/2016 – Bank of America Merrill Lynch began new coverage on Amicus Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 10 price target on the stock.
04/13/2016 – Robert W. Baird began new coverage on Amicus Therapeutics, Inc. giving the company a “neutral” rating. They now have a USD 9 price target on the stock.
04/12/2016 – Amicus Therapeutics, Inc. had its “buy” rating reiterated by analysts at Chardan Capital. They now have a USD 15 price target on the stock.
03/30/2016 – Amicus Therapeutics, Inc. had its “neutral” rating reiterated by analysts at Goldman Sachs. They now have a USD 10 price target on the stock.
03/08/2016 – Amicus Therapeutics, Inc. was upgraded to “buy” by analysts at Janney Montgomery Scott.
10/05/2015 – Amicus Therapeutics, Inc. had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 13 price target on the stock.
09/08/2015 – Amicus Therapeutics, Inc. had its “overweight” rating reiterated by analysts at JP Morgan. They now have a USD 28 price target on the stock.
06/16/2015 – Amicus Therapeutics, Inc. had its “buy” rating reiterated by analysts at B. Riley. They now have a USD 17.5 price target on the stock.
05/08/2015 – Amicus Therapeutics, Inc. was downgraded to “sell” by analysts at Zacks.
Amicus Therapeutics, Inc. has a 50 day moving average of 6.43 and a 200 day moving average of 6.86. The stock’s market capitalization is 1.02B, it has a 52-week low of 4.98 and a 52-week high of 18.40.
The share price of the company (FOLD) was up +2.56%, with a high of 7.20 during the day and the volume of Amicus Therapeutics, Inc. shares traded was 1317417.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD). It has completed two Phase III global registration studies (Study 011 and Study 012) of migalastat monotherapy. It is also engaged in Phase III clinical development of a topical cream, SD-101, for the treatment of the genetic connective tissue disorder Epidermolysis Bullosa. It has also initiated a clinical study in patients with Pompe disease, a LSD to investigate its treatment paradigm that consists of ATB200, which is an engineered recombinant human acid alpha-glucosidase enzyme with an optimized carbohydrate structure to enhance uptake, co-administered with AT2221, to improve activity and stability.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'